Position in SVTR
Snapshot 2026-10-28- Startup SignalsTop 50%new
- Life SciencesTop 50%
- AI for ScienceTop 50%
- Drug DiscoveryTop 50%
About
BioGeometry is an AI-native biopharma company using geometric deep learning and generative AI to design proteins and antibodies; its GeoFlow generative biomolecule model and GeoBiologics platform are coupled with high-throughput wet-lab validation, with 20+ BD partnerships with pharma companies.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 6
Founders / team· 1
Funding history
- 2026-10-28Series A+
Investors · 国寿资本, 上海生物医药基金, 国开科创, 瑞力投资, 国方创投, Fortune CapitalSource · chinaventure.com.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- BioGeometry
BioGeometry is an AI-native biopharma company using geometric deep learning and generative AI to design proteins and antibodies; its GeoFlow generative biomolecule model and GeoBiologics platform are coupled with high-throughput wet-lab validation, with 20+ BD partnerships with pharma companies.
Series A · $100M · 2026-10
$100M
United States
BusinessLatest roundTotal raisedDate- Aureka Biotechnologies
AuraIDE™, a platform for generative antibody drug discovery and functional antibody design
Series B · $200M · 2026-08
$200M - Profluent
Develops generative AI and foundation models for protein design (ProGen3, E1, OpenCRISPR, etc.)
Undisclosed · $141M · 2025-11
$141M - Ten63 Therapeutics
Applies generative AI models to drug discovery and development
$54M · 2026-03
$54M
China
BusinessLatest roundTotal raisedDate- Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B
Europe
BusinessLatest roundTotal raisedDate- Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M - Cradle
AI that helps scientists design and engineer proteins faster and more cost-effectively
Undisclosed · $106M · 2024-12
$106M
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Mithril Medicine
Mithril Medicine was a one-person biotech founded by Cody Tranbarger with Atlas Venture backing, developing antibody therapies for two rare muscular dystrophies (LAMA2-CMD and alpha-dystroglycanopathy). Using Claude to coordinate contracts, logistics and experiments across 11 external labs, it took one program from idea to promising mouse results in under 18 months.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in North China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 5 at a nearby stage · 4 in North China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in North China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in North China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 3 at a nearby stage · 6 in North China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 6 at a nearby stage · 4 in North China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.